Botulinum Toxin Treatment on Migraine Patients; Its Effect on Disability, Severity of Migraine and Depression

Objective: Migraine patients have a high risk of developing anxiety and depression, and the relationship between chronic migraine (CM) and depression is believed to be bidirectional.This study aims to evaluate the effects of Botulinum Neurotoxin A (BoNT/A) treatment on migraine-related disability, pain severity, and depression in patients with CM. Materials and Methods:This study included 24 patients aged between 19 and 55 years who were diagnosed with CM and treated with BoNT/A injections every 12 weeks for six months.Data were collected on demographic characteristics, as well as disability severity, pain severity, and depression levels before and after treatment.Results: A statistically significant improvement was observed in VAS (Visual Analog Scale), MIDAS (Migraine Disability Assessment Scale), and BDS (Beck Depression Scale) scores after BoNT/A treatment (p<0.001).The mean changes in scores were as follows: a 41-point reduction in VAS, a 6123-point reduction in MIDAS, and a 169-point reduction in BDS.Patients reported experiencing initial treatment benefits within 123 days, with an average duration of effect lasting 9338 days. Conclusion:BoNT/A treatment appears to play a significant role in modulating pain perception and emotional responses, particularly in patients with depression and those resistant to conventional migraine treatments.The findings suggest that BoNT/A may be an effective treatment option for reducing migraine-related disability, pain severity, and associated depressive symptoms.